These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 24906437)

  • 1. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.
    Imanaka K; Tominaga Y; Etropolski M; Ohashi H; Hirose K; Matsumura T
    Clin Drug Investig; 2014 Jul; 34(7):501-11. PubMed ID: 24906437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain.
    Steigerwald I; Schenk M; Lahne U; Gebuhr P; Falke D; Hoggart B
    Clin Drug Investig; 2013 Sep; 33(9):607-19. PubMed ID: 23912473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.
    Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Lange B; Dogan C; Etropolski MS; Eerdekens M
    Pain Physician; 2014; 17(4):329-43. PubMed ID: 25054392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
    Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
    Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study.
    Afilalo M; Etropolski MS; Kuperwasser B; Kelly K; Okamoto A; Van Hove I; Steup A; Lange B; Rauschkolb C; Haeussler J
    Clin Drug Investig; 2010; 30(8):489-505. PubMed ID: 20586515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose conversion between tapentadol immediate and extended release for low back pain.
    Etropolski MS; Okamoto A; Shapiro DY; Rauschkolb C
    Pain Physician; 2010; 13(1):61-70. PubMed ID: 20119464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral tapentadol for cancer pain.
    Wiffen PJ; Derry S; Naessens K; Bell RF
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD011460. PubMed ID: 26403220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials.
    Etropolski M; Kuperwasser B; Flügel M; Häufel T; Lange B; Rauschkolb C; Laschewski F
    Adv Ther; 2014 Jun; 31(6):604-20. PubMed ID: 24985410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain.
    Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Dogan C; Etropolski M; Eerdekens M
    Eur J Pain; 2016 Oct; 20(9):1513-8. PubMed ID: 27062079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.
    Merchant S; Noe LL; Howe A; Duff S; Gricar J; Ogden K; Mody SH
    Clin Ther; 2013 May; 35(5):659-72. PubMed ID: 23587608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial.
    Buynak R; Rappaport SA; Rod K; Arsenault P; Heisig F; Rauschkolb C; Etropolski M
    Clin Ther; 2015 Nov; 37(11):2420-38. PubMed ID: 26428249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.
    Schwartz S; Etropolski M; Shapiro DY; Okamoto A; Lange R; Haeussler J; Rauschkolb C
    Curr Med Res Opin; 2011 Jan; 27(1):151-62. PubMed ID: 21162697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain.
    Imanaka K; Tominaga Y; Etropolski M; van Hove I; Ohsaka M; Wanibe M; Hirose K; Matsumura T
    Curr Med Res Opin; 2013 Oct; 29(10):1399-409. PubMed ID: 23937387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
    Afilalo M; Morlion B
    Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tapentadol for chronic musculoskeletal pain in adults.
    Santos J; Alarcão J; Fareleira F; Vaz-Carneiro A; Costa J
    Cochrane Database Syst Rev; 2015 May; 2015(5):CD009923. PubMed ID: 26017279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial.
    Baron R; Jansen JP; Binder A; Pombo-Suarez M; Kennes L; Müller M; Falke D; Steigerwald I
    Pain Pract; 2016 Jun; 16(5):600-19. PubMed ID: 26554630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study.
    Baron R; Likar R; Martin-Mola E; Blanco FJ; Kennes L; Müller M; Falke D; Steigerwald I
    Pain Pract; 2016 Jun; 16(5):580-99. PubMed ID: 26095455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain.
    Biondi DM; Xiang J; Etropolski M; Moskovitz B
    J Opioid Manag; 2015; 11(5):393-403. PubMed ID: 26535967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain.
    Sánchez Del Águila MJ; Schenk M; Kern KU; Drost T; Steigerwald I
    Clin Ther; 2015 Jan; 37(1):94-113. PubMed ID: 25108647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.
    Steigerwald I; Müller M; Davies A; Samper D; Sabatowski R; Baron R; Rozenberg S; Szczepanska-Szerej A; Gatti A; Kress HG
    Curr Med Res Opin; 2012 Jun; 28(6):911-36. PubMed ID: 22443293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.